常任理事

Medicine & Life Sciences

1. Abatacept 15%
2. Adalimumab 16%
3. Adenocarcinoma 12%
4. Antibodies 14%
5. Antirheumatic Agents 17%
6. Atopic Dermatitis 10%
7. Autoantibodies 22%
8. Autoimmune Diseases 10%
9. B-Lymphocytes 8%
10. baricitinib 15%
11. Biomarkers 12%
12. Blister 9%
13. Bone and Bones 13%
14. Breast Neoplasms 16%
15. Bullous Pemphigoid 11%
16. C-Reactive Protein 9%
17. Carcinoma 12%
18. Chemoradiotherapy 19%
19. Cisplatin 16%
20. Cohort Studies 10%
21. Colorectal Neoplasms 19%
22. Desmoglein 1 14%
23. Desmoglein 3 33%
24. Desmogleins 15%
25. Docetaxel 8%
26. Drug Therapy 20%
27. Esophageal Neoplasms 66%
28. Esophageal Squamous Cell Carcinoma 33%
29. Esophagectomy 49%
30. Esophagus 10%
31. Etanercept 9%
32. filaggrin 9%
33. Fluorouracil 17%
34. Gastrectomy 16%
35. Gastrointestinal Neoplasms 12%
36. Genes 11%
37. Hepatocellular Carcinoma 10%
38. Immunoglobulin G 17%
39. Immunoglobulin G4-Related Disease 12%
40. Incidence 13%
41. Infliximab 13%
42. Interleukin-6 10%
43. Japan 48%
44. Joints 21%
45. Keratinocytes 9%
46. Knee 13%
47. Laminoplasty 13%
48. Laparoscopy 18%
49. Liver 18%
50. Liver Transplantation 20%
51. Living Donors 18%
52. Lung 8%
53. Lymph Node Excision 14%
54. Lymph Nodes 27%
55. Magnetic Resonance Imaging 11%
56. Methotrexate 39%
57. Multicenter Studies 10%
58. Neoplasm Metastasis 37%
59. Neoplasms 43%
60. Neural Stem Cells 10%
61. Ossification of Posterior Longitudinal Ligament 17%
62. Osteoclasts 9%
63. Pancreatic Neoplasms 14%
64. Pancreaticoduodenectomy 8%
65. peficitinib 9%
66. Pemphigus 56%
67. Placebos 15%
68. Pneumonia 8%
69. Postoperative Complications 12%
70. Prospective Studies 10%
71. Recurrence 23%
72. Retrospective Studies 11%
73. Rheumatoid Arthritis 100%
74. Rheumatology 11%
75. Safety 37%
76. Scoliosis 12%
77. Sentinel Lymph Node 25%
78. Serum 18%
79. Skin 17%
80. Spinal Cord 14%
81. Spinal Cord Diseases 11%
82. Spinal Cord Injuries 13%
83. Spine 22%
84. Squamous Cell Carcinoma 9%
85. Stem Cells 10%
86. Stomach 16%
87. Stomach Neoplasms 48%
88. Surgical Wound Infection 9%
89. Survival 22%
90. Systematic Reviews 8%
91. Systemic Lupus Erythematosus 15%
92. T-Lymphocytes 9%
93. Therapeutics 32%
94. Thorax 17%
95. tocilizumab 26%
96. Tomography 9%
97. Transplantation 10%
98. Transplants 16%
99. Wounds and Injuries 9%